Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04582864 · ClinicalTrials.gov registry record · Phase 2
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04582864 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 11 participants.
The verdict
NCT04582864, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional therapeutic efficacy.
Interventions
- DRUG Flotetuzumab
- PROCEDURE Donor lymphocyte infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2024-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04582864
The ClinicalTrials.gov registry entry for NCT04582864 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flotetuzumab is the first listed.
NCT04582864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04582864 about?
NCT04582864 is a clinical study titled "Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)". The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if ...
What is the current status of trial NCT04582864?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2021-05-20. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT04582864?
The interventions under investigation include: Flotetuzumab (DRUG), Donor lymphocyte infusion (PROCEDURE).
Who is sponsoring clinical trial NCT04582864?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.